Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Estatinas para el hígado graso no alcohólico y la esteatohepatitis no alcohólica

Información

DOI:
https://doi.org/10.1002/14651858.CD008623.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 27 diciembre 2013see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Hepatobiliar

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Layli Eslami

    Correspondencia a: Golestan University of Medical Science, Taleghani Hospital, Gonbad e Kavous, Iran

    [email protected]

  • Shahin Merat

    Digestive Diseases Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

  • Reza Malekzadeh

    Digestive Diseases Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

  • Siavosh Nasseri‐Moghaddam

    Digestive Diseases Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

  • Hermineh Aramin

    Digestive Diseases Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Contributions of authors

Formulating the research question: Reza Malekzadeh (RM), Layli Eslami (LE), and Siavosh Nasseri‐Moghaddam (SNM).
Writing up the protocol: LE with comments from SNM and Shahin Merat (SM).
Searching: Cochrane Hepato‐Biliary Group (CHBG).
Selecting and reviewing eligible studies: LE and SNM.
Performing methodological assessment and extraction of data: LE.
Providing data entry and management: LE.
Performing data analysis: LE.
Preparing the manuscript: LE, Hermineh Aramin (HA), and SNM.

Sources of support

Internal sources

  • Tehran University of Medical Sciences (TUMS), Iran.

External sources

  • No sources of support supplied

Declarations of interest

None known.

Acknowledgements

Our special thanks goes to Dimitrinka Nikolova and Sarah Louise Klingenberg in The Cochrane Hepato‐Biliary Group (CHBG) for their unlimited help in preparing this review.

Peer reviewers: Mona H Ismail, Saudi Arabia; Yusuf Yilmaz, Turkey; Raj Vuppalanchi, USA.
Contact editor: Christian Gluud, Denmark.

Version history

Published

Title

Stage

Authors

Version

2013 Dec 27

Statins for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis

Review

Layli Eslami, Shahin Merat, Reza Malekzadeh, Siavosh Nasseri‐Moghaddam, Hermineh Aramin

https://doi.org/10.1002/14651858.CD008623.pub2

2010 Jul 07

Statins for non‐alcoholic steatohepatitis

Protocol

Layli Eslami, Shahin Merat, Reza Malekzadeh, Siavosh Nasseri‐Moghaddam, Hermineh Aramin

https://doi.org/10.1002/14651858.CD008623

Differences between protocol and review

As the result of recent changes in Cochrane requirements, the order of outcomes in this review has been changed so that they reflect the needs of consumers.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 1

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Search results

Source of the search

Number of records

CHBG Controlled Trial Register

51

Cochrane Central Register of Controlled Trials

78

MEDLINE (Ovid)

116

EMBASE (Ovid)

518

Science Citation Index EXPANDED

91

Total number of references identified

851

Number of duplicates excluded

198

Number of references in final list

653
Figuras y tablas -
Table 1. Search results
Ir a la tabla de la revisión
Table 2. Baseline and after treatment laboratory variables in Nelson et al trial

 

Statin (n = 10)

Placebo  (n = 6)

Before treatment

After treatment

Mean decrease

Before treatment

After treatment

Mean decrease

ALT (U/L)

70.4

49.5

20.9

66.8

75.3

‐8.5

AST (U/L)

43.3

36.5

6.8

42.8

49.3

‐6.5

ALP (U/L)

86.1

89.7

‐3.6

74.3

73

1.3

TG (mg/dL)

388.7

490

‐101.3

335.3

361.7

‐26.4

ALT = alanine aminotransferase
AST = aspartate aminotransferase
ALP = alkaline phosphatase
TG = triglycerides

Figuras y tablas -
Table 2. Baseline and after treatment laboratory variables in Nelson et al trial
Ir a la tabla de la revisión
Table 3. Baseline and after treatment laboratory variables in Athyros et al trial

 

Statin (n = 63)

Fenofibrate  (n = 62)

Before treatment

After treatment

Mean decrease

Before treatment

After treatment

Mean decrease

ALT (U/L)

54

32

22

52

36

16

AST (U/L)

38

25

13

39

27

12

ALP (U/L)

110

75

35

108

78

30

TG (mg/dL)

203.8

142.2

61.6

194.9

115.6

79.3

ALT = alanine aminotransferase
AST = aspartate aminotransferase
ALP = alkaline phosphatases
TG = triglycerides

Figuras y tablas -
Table 3. Baseline and after treatment laboratory variables in Athyros et al trial
Ir a la tabla de la revisión
Table 4. Level of evidence for each outcome

Outcome

Biochemical improvement

 

Radiological improvement

No improvement in histology

Serious adverse effects

Evidence

Low‐quality systematic review

Low‐quality randomised clinical trial

Small sample size in low‐quality randomised clinical trial

Low‐quality systematic review

 

Level of evidence

2

2

2

2

Grade of recommendation

B

B

B

B
Figuras y tablas -
Table 4. Level of evidence for each outcome
Ir a la tabla de la revisión